Report #2864996

Received Oct 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 75 yrs
State: —
Recovered: Unknown
Vaccinated: Sep 29, 2025
Onset: Sep 29, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	342xp	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

early 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 75-year-old male patient who received Herpes zoster (Shingrix) (batch number 342xp, expiry date 28-APR-2027) for prophylaxis. Concomitant products included Herpes zoster (Shingrix). On 29-SEP-2025, the patient received the 2nd dose of Shingrix. On 29-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: early 2nd dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 30-SEP-2025 The pharmacist reported that the patient received his first dose of Shingrix on 18-Sep-25 and second dose on 29-Sep-25.